Mourabit Halima, Author at MediaMedic

Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

By Mourabit Halima 2024.07.12

Clinical cure of chronic hepatitis B (CHB), also known as functional cure, is achieved when patients remain HBsAg negative after stopping treatment, with or without the presence of anti-HBs, HBV DNA levels below the detection limit, and normal liver biochemical indicators. However, HBV covalently closed circular DNA (cccDNA) may still persist in the nuclei of liver cells in these patients. Therefore, clearing HBV cccDNA remains a major obstacle to achieving complete virological cure of CHB. Recently, at the 17th National Clinical Conference on Liver Diseases held in Shenyang, "Hepatology Digest" invited Professor Jun Cheng from Hebei Wutu Pharmaceutical Co., Ltd. to discuss the clearance of HBV cccDNA and other related issues.

Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

By Mourabit Halima 2024.07.12

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage breast cancer, CDK4/6 inhibitors have also shown positive results and have been approved for indications. The 2024 ASCO conference presented multiple advancements in the adjuvant treatment of HR+/HER2- early-stage breast cancer with CDK4/6 inhibitors. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum, Oncology Frontier invited Professor Hong Hu from Shenzhen People's Hospital, and Professor Yuntao Wei from Liaoning Cancer Hospital & Institute to elaborate on and discuss the research progress of CDK4/6 inhibitors in adjuvant therapy for HR+ early-stage breast cancer.

Professor Houwen Lin: The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases

By Mourabit Halima 2024.07.10

With the increasing aging population in China, major chronic diseases have become the leading cause of death and the most significant disease burden for Chinese residents. As an essential means of treating chronic diseases, medications urgently require scientific, rational, and precise usage and management. At a domestic academic conference, Professor Houwen Lin from Shanghai Jiao Tong University School of Medicine, gave a remarkable academic report titled "The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases." He provided a detailed introduction of how the clinical pharmacy team at Renji Hospital, driven by clinical needs, established key technologies for precise medication and new drug clinical positioning for major chronic diseases such as cardiovascular metabolism, rheumatology, and oncology. This article summarizes the report's content for the readers of Hepatology Digest.

ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

By Mourabit Halima 2024.07.10

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. During this prestigious event, Oncology Frontier-Hematology Frontier had the honor of interviewing Academician Heyu Ni from the Canadian Academy of Health Sciences, who also served as the Chair of the Joint ISTH Congress and Global Chinese Thrombosis and Hemostasis Conference. In this interview, Academician Ni shared his extensive academic experience and unique insights, providing us with valuable academic reflections and perspectives. We have organized this interview into an article for our readers.

Xinghai Forum: Professor Bin Hua and Juliang Zhang Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast

By Mourabit Halima 2024.07.10

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Bin Hua from Beijing Hospital and Professor Juliang Zhang from Xijing Hospital of Air Force Medical University discuss these latest research advancements in depth.

ISTH China’s Voice | Professor Xuefeng Wang’s Team: Single-cell sequencing of PBMCs from hemophilia A and hemophilia B patients with inhibitors reveals different immune responses to FVIII and FIX after replacement therapy

By Mourabit Halima 2024.07.10

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars worldwide with its profound academic impact and rich content. The "ISTH China's Voices" column of Oncology Frontier-Hematology Frontier aims to showcase outstanding research achievements from the Chinese academic community at ISTH. In this issue, we present a research finding from Dr. Enhao Li of Professor Xuefeng Wang's team at Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li's oral presentation at ISTH delved into the differential immune responses to FVIII and FIX in hemophilia A (HA) and hemophilia B (HB) patients, providing valuable academic insights for the hematology field.

Professor Sifeng Tao and Hui Liu Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast Cancer

By Mourabit Halima 2024.07.10

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Sifeng Tao from The Second Affiliated Hospital Zhejiang University School of Medicine and Professor Hui Liu fro

ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

By Mourabit Halima 2024.07.10

CDL (China Diabetes and Liver Disease Co-management Action Plan) Literature Monthly Review—June 2024, Issue 17

By Mourabit Halima 2024.07.10

Diabetes and liver disease are prevalent chronic conditions in China. They often interact in terms of pathogenesis, clinical manifestations, and treatment targets, acting as mutual risk factors. Joint management can alleviate the disease burden. To support the development of co-management of diabetes and liver disease in China, this journal, in collaboration with the CDL (China Diabetes and Liver Disease Co-management Action Plan), launches the CDL Literature Monthly Review column. Each month, we share relevant research on the mechanisms and treatment advancements of diabetes combined with liver disease, inviting experts in the field to provide commentary. This aims to offer insights and assistance to researchers and frontline medical professionals in scientific research and clinical practice.

Case Sharing: A Case of Hepatic Sinusoidal Obstruction Syndrome Induced by Combined Drug and Alcohol Use

By Mourabit Halima 2024.07.09

Hepatic sinusoidal obstruction syndrome (HSOS), also known as hepatic veno-occlusive disease, is a common secondary vascular liver disease caused by various factors leading to damage to sinusoidal endothelial cells, resulting in sinusoidal obstruction and hepatic congestion. Clinically, it primarily presents with abdominal distension, liver pain, rapid ascites accumulation, hepatomegaly, and jaundice, which can lead to severe liver dysfunction, multi-organ failure, and even death. Professor Qingchun Fu's team from the Shanghai Public Health Clinical Center shares a clinical case and their experience in diagnosing and treating a patient with HSOS induced by combined drug and alcohol use.